Atazanavir Ritonavir ABC-3TC SHARE Trial Results
Explore the results of the Atazanavir, Ritonavir, Abacavir-Lamivudine (ABC-3TC) SHARE Trial at Week 48, showcasing virologic response and changes in fasting lipids from baseline. Find out how this regimen proves to be effective and well-tolerated in treatment-naïve patients with HIV infection.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
Atazanavir + Ritonavir + ABC-3TC SHARE Trial
Atazanavir + Ritonavir + ABC-3TC in Treatment-Nave SHARE: Study Design Study Design: SHARE Background: Nonrandomized, open-label, single-arm pilot study evaluating the efficacy and safety of once-daily abacavir-lamivudine plus ritonavir-boosted atazanavir in treatment-na ve adults with HIV infection Atazanavir + ritonavir + ABC- 3TC (n = 111) Inclusion Criteria (n = 112) - Age 18 - Antiretroviral treatment-na ve - HIV RNA 5000 copies/mL - No AIDS-defining illnesses in previous 30 days Treatment Arms (All Once daily) - Atazanavir 300 mg + Ritonavir 100 mg + Abacavir-Lamivudine 600/300 mg Source: Elion R, et al. HIV Clin Trials. 2008;9:152-63.
Atazanavir + Ritonavir + ABC-3TC in Treatment-Nave SHARE: Results Week 48: Virologic Response, by Baseline HIV RNA (ITT, M=F) 100 HIV RNA <50 copies/mL (%) 77 77 76 80 60 40 20 0 All <100,000 copies/mL 100,000 copies/mL Baseline HIV RNA Source: Elion R, et al. HIV Clin Trials. 2008;9:152-63.
Atazanavir + Ritonavir + ABC-3TC in Treatment-Nave SHARE: Results Week 48: Change in Fasting Lipids from Baseline Atazanavir + Ritonavir + ABC-3TC 60 Median Change from Baseline (95% CI) 50 45 40 30 30 20 13 9 10 0 Total Cholesterol LDL Cholesterol HDL Cholesterol Triglycerides Source: Elion R, et al. HIV Clin Trials. 2008;9:152-63.
Atazanavir/r + ABC-3TC in Treatment-Nave SHARE: Conclusions Conclusion: ABC/3TC and ATV-RTV QD is an effective and well- tolerated regimen in ART-na ve patients through 48 weeks, with a modest impact on fasting lipids. Source: Elion R, et al. HIV Clin Trials. 2008;9:152-63.
Acknowledgment The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center. The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.
